TW200745116A - Macrocylic inhibitors of hepatitis C virus - Google Patents

Macrocylic inhibitors of hepatitis C virus

Info

Publication number
TW200745116A
TW200745116A TW095127585A TW95127585A TW200745116A TW 200745116 A TW200745116 A TW 200745116A TW 095127585 A TW095127585 A TW 095127585A TW 95127585 A TW95127585 A TW 95127585A TW 200745116 A TW200745116 A TW 200745116A
Authority
TW
Taiwan
Prior art keywords
c6alkyl
hydrogen
hepatitis
virus
crz
Prior art date
Application number
TW095127585A
Other languages
English (en)
Other versions
TWI387597B (zh
Inventor
Pierre Jean-Marie Raboisson
Kock Herman Augustinus De
Li-Li Hu
Kenneth Alan Simmen
Karin Charlotta Lindquist
Mats Stefan Lindstrom
Anna Karin Gertrud Linnea Belfrage
Horst Juergen Waehling
Karl Magnus Nilsson
Bengt Bertil Samuelsson
Asa Annica Kristina Rosenquist
Sven Crister Sahlberg
Hans Kristian Wallberg
Pia Cecilia Kahnberg
Bjorn Olof Classon
Original Assignee
Medivir Ab
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37708968&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200745116(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivir Ab, Tibotec Pharm Ltd filed Critical Medivir Ab
Publication of TW200745116A publication Critical patent/TW200745116A/zh
Application granted granted Critical
Publication of TWI387597B publication Critical patent/TWI387597B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW095127585A 2005-07-29 2006-07-28 Ｃ型肝炎病毒之大環抑制劑 TWI387597B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05107057 2005-07-29
EP06113097 2006-04-25

Publications (2)

Publication Number Publication Date
TW200745116A true TW200745116A (en) 2007-12-16
TWI387597B TWI387597B (zh) 2013-03-01

Family

ID=37708968

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095127585A TWI387597B (zh) 2005-07-29 2006-07-28 Ｃ型肝炎病毒之大環抑制劑

Country Status (32)

Country Link
US (1) US7659245B2 (zh)
EP (1) EP1912981B1 (zh)
JP (1) JP5230418B2 (zh)
KR (1) KR101083631B1 (zh)
AP (1) AP2585A (zh)
AR (1) AR057702A1 (zh)
AT (1) ATE455775T1 (zh)
AU (1) AU2006274866B2 (zh)
BR (1) BRPI0614153A2 (zh)
CA (1) CA2617103C (zh)
CY (1) CY1110008T1 (zh)
DE (1) DE602006011905D1 (zh)
DK (1) DK1912981T3 (zh)
EA (1) EA014188B1 (zh)
ES (1) ES2339702T3 (zh)
GT (1) GT200600343A (zh)
HK (1) HK1116488A1 (zh)
HR (1) HRP20100209T1 (zh)
IL (1) IL188320A (zh)
ME (1) ME01454B (zh)
MY (1) MY151026A (zh)
NO (1) NO20081075L (zh)
NZ (1) NZ564540A (zh)
PE (1) PE20070343A1 (zh)
PL (1) PL1912981T3 (zh)
PT (1) PT1912981E (zh)
RS (1) RS51227B (zh)
SI (1) SI1912981T1 (zh)
SV (1) SV2008002641A (zh)
TW (1) TWI387597B (zh)
UY (1) UY29704A1 (zh)
WO (1) WO2007014927A2 (zh)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
CA2552319C (en) 2004-01-30 2012-08-21 Medivir Ab Hcv ns-3 serine protease inhibitors
ES2449540T3 (es) 2005-07-29 2014-03-20 Janssen R&D Ireland Inhibidores macrocíclicos del virus de la hepatitis C
JO2768B1 (en) * 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
EP1912997B1 (en) 2005-07-29 2011-09-14 Tibotec Pharmaceuticals Macrocyclic inhibitors of hepatitis c virus
CA2624333A1 (en) 2005-10-11 2007-04-19 Intermune, Inc. Compounds and methods for inhibiting hepatitis c viral replication
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20090024834A (ko) 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
KR101512477B1 (ko) 2006-07-13 2015-04-15 아칠리온 파르마세우티칼스 인코포레이티드 바이러스 복제 억제제로서 사용되는 4-아미노-4-옥소부타노일 펩티드
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR064258A1 (es) * 2006-11-17 2009-03-25 Tibotec Pharm Ltd Inhibidores macrociclicos del virus de hepatitis c
CA2677173C (en) * 2007-02-01 2017-12-12 Tibotec Pharmaceuticals Ltd. Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
US8937080B2 (en) * 2007-02-08 2015-01-20 Medivir Ab Pyrimidine substituted macrocyclic HCV inhibitors
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
CA2700383A1 (en) * 2007-09-24 2009-04-02 Achillion Pharmaceuticals, Inc. Urea-containing peptides as inhibitors of viral replication
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8426360B2 (en) * 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
US8263549B2 (en) 2007-11-29 2012-09-11 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
EP2226315A4 (en) 2007-12-28 2012-01-25 Carna Biosciences Inc 2-AMINOQUINAZOLINE DERIVATIVE
MX2010010276A (es) 2008-03-20 2011-03-25 Enanta Pharm Inc Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c.
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044023B2 (en) 2008-05-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DK2364309T3 (en) 2008-12-10 2015-01-12 Achillion Pharmaceuticals Inc NEW 4-AMINO-4-OXOBUTANOYLPEPTIDER as inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BRPI1008918A2 (pt) 2009-02-27 2016-03-15 Ortho Mcneil Janssen Pharm sal amorfo de um inibidor macrocíclico de hcv
JP2012523419A (ja) 2009-04-08 2012-10-04 イデニク プハルマセウティカルス，インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
EA201101673A1 (ru) * 2009-05-29 2012-10-30 Зингента Партисипейшнс Аг Замещенные хиназолины в качестве фунгицидов
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
EP2658859A4 (en) 2010-12-30 2014-07-30 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
SG191759A1 (en) 2010-12-30 2013-08-30 Enanta Pharm Inc Phenanthridine macrocyclic hepatitis c serine protease inhibitors
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2558608T3 (es) 2011-12-28 2016-02-05 Janssen Sciences Ireland Uc Derivados hetero-bicíclicos como inhibidores del VHC
WO2014062428A1 (en) * 2012-10-15 2014-04-24 Albemarle Corporation Processes for the synthesis of 2-amino-4,6-dimethoxybenzamide and other benzamide compounds
SG11201502802PA (en) 2012-10-19 2015-05-28 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014145507A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP3108879A1 (en) 2015-06-25 2016-12-28 Cassiopea S.p.A. High concentration formulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
KR20110028665A (ko) 2002-04-11 2011-03-21 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 ｃ형 간염 바이러스 ｎｓ3-ｎｓ4 프로테아제의 억제제
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
EP1590442A4 (en) * 2003-02-07 2007-07-18 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
US20040180815A1 (en) * 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
EP2033654B1 (en) * 2003-04-16 2012-05-16 Bristol-Myers Squibb Company Process for resolving a mixture of alkyl ester enantiomers using an enzyme
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
ATE500264T1 (de) * 2003-09-22 2011-03-15 Boehringer Ingelheim Int Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus
CA2552319C (en) * 2004-01-30 2012-08-21 Medivir Ab Hcv ns-3 serine protease inhibitors
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
JP5171624B2 (ja) * 2005-07-29 2013-03-27 テイボテク・フアーマシユーチカルズ Ｃ型肝炎ウイルスの大環状阻害剤
WO2007017144A2 (en) * 2005-07-29 2007-02-15 Medivir Ab Macrocylic inhibitors of hepatitis c virus
WO2007014920A1 (en) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus

Also Published As

Publication number Publication date
RS51227B (sr) 2010-12-31
AR057702A1 (es) 2007-12-12
HRP20100209T1 (hr) 2010-05-31
US7659245B2 (en) 2010-02-09
SI1912981T1 (sl) 2010-05-31
EP1912981A2 (en) 2008-04-23
JP5230418B2 (ja) 2013-07-10
CA2617103A1 (en) 2007-02-08
NO20081075L (no) 2008-04-25
TWI387597B (zh) 2013-03-01
NZ564540A (en) 2010-03-26
CY1110008T1 (el) 2015-01-14
AP2585A (en) 2013-02-04
ME01454B (me) 2014-04-20
KR101083631B1 (ko) 2011-11-16
ES2339702T3 (es) 2010-05-24
WO2007014927A3 (en) 2007-11-29
CA2617103C (en) 2015-01-06
KR20080033475A (ko) 2008-04-16
SV2008002641A (es) 2008-07-23
US20090118312A1 (en) 2009-05-07
ATE455775T1 (de) 2010-02-15
EA200800482A1 (ru) 2008-06-30
HK1116488A1 (en) 2008-12-24
AU2006274866B2 (en) 2012-04-12
DK1912981T3 (da) 2010-05-25
PE20070343A1 (es) 2007-05-12
BRPI0614153A2 (pt) 2011-03-15
UY29704A1 (es) 2007-05-31
AU2006274866A1 (en) 2007-02-08
EA014188B1 (ru) 2010-10-29
IL188320A (en) 2014-07-31
MY151026A (en) 2014-03-31
JP2009502890A (ja) 2009-01-29
PT1912981E (pt) 2010-04-16
WO2007014927A2 (en) 2007-02-08
EP1912981B1 (en) 2010-01-20
IL188320A0 (en) 2008-04-13
DE602006011905D1 (de) 2010-03-11
PL1912981T3 (pl) 2010-07-30
GT200600343A (es) 2007-08-06

Similar Documents

Publication Publication Date Title
TW200745116A (en) Macrocylic inhibitors of hepatitis C virus
WO2007017144A3 (en) Macrocylic inhibitors of hepatitis c virus
TW200801044A (en) Macrocylic inhibitors of hepatitis C virus
MX2009005219A (es) Inhibidores macrociclicos del virus de hepatitis c.
MX337050B (es) Compuestos 4'-azido-nucleósidos como anti-vhc.
MXPA05009771A (es) Derivados heterociclicos que contienen nitrogeno y medicamentos que los contienen como el ingrediente activo.
GEP20115347B (en) Heterocyclocarboxamide derivatives
MXPA05009059A (es) Derivados de heteroarilcarbamoilbenceno.
IN2012DN00999A (zh)
MY153393A (en) Amino nicotinic and isonicotinic acid derivatives as dhodh as inhibitors
MX2009013728A (es) Derivados de bicicloanilina.
MY154772A (en) Harmful arthropod control composition, and fused heterocyclic compound
CO5570663A2 (es) Derivados del acido mandelico
MY160443A (en) Nitrogen-containing heterocyclic compound and agricultural fungicide
MX2012007420A (es) Analogos para el tratamiento o prevencion de infecciones de flavivirus.
EP1736471A4 (en) 3- (DIHYDRO (tetrahydro) isoquinolin-1-YL) QUINOLINES
DE60309836D1 (de) Kristalline zeolithische aluminosilikat-zusammensetzung: uzm-9
NO20053570L (no) Termostabilt, vannopploselig polymer som er tverrbindbar ved hoye temperaturer
WO2008005519A3 (en) Novel pyridazine compound and use thereof
TW200600085A (en) External preparation
WO2003035620A1 (fr) Compose bicyclique
UA93377C2 (ru) Макроциклические ингибиторы вируса гепатита c
PT2513115E (pt) Antibióticos tricíclicos
TW200738681A (en) Isoquinoline and benzo[h]isoquinoline derivatives, their preparation and their use in therapeutics
WO2008042497A3 (en) Benzoxazole and benzothiazole compounds useful as authentication compounds in polymer articles

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees